• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.

作者信息

Sodhi Mohit, Rezaeianzadeh Ramin, Kezouh Abbas, Etminan Mahyar

机构信息

Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

StatExpert Ltd, Laval, Quebec, Canada.

出版信息

JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574.

DOI:10.1001/jama.2023.19574
PMID:37796527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10557026/
Abstract
摘要

相似文献

1
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.胰高血糖素样肽-1受体激动剂用于减肥时胃肠道不良事件的风险
JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574.
2
Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.胰高血糖素样肽-1受体激动剂与心血管疾病：从LEADER研究到EXSCEL研究
Cardiovasc Res. 2018 Aug 1;114(10):e70-e71. doi: 10.1093/cvr/cvy124.
3
Role of glucagon-like peptide 1 receptor agonists in management of obesity.胰高血糖素样肽-1受体激动剂在肥胖管理中的作用。
Am J Health Syst Pharm. 2016 Oct 1;73(19):1493-507. doi: 10.2146/ajhp150990. Epub 2016 Aug 12.
4
Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?胰高血糖素样肽-1受体激动剂：维持健康体重减轻的关键？
Cardiovasc Res. 2021 Aug 29;117(10):e120-e122. doi: 10.1093/cvr/cvab249.
5
[Not Available].[无可用内容]。
Ther Umsch. 2017;74(8):433-439. doi: 10.1024/0040-5930/a000937.
6
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.GLP-1 受体激动剂在无糖尿病肥胖/超重患者中的减肥效果和安全性：系统评价和荟萃分析。
Horm Metab Res. 2022 Jul;54(7):458-471. doi: 10.1055/a-1844-1176. Epub 2022 May 5.
7
Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?是否到了为没有糖尿病的患者扩大使用胰高血糖素样肽-1 受体激动剂来减肥的时候了？
Drugs. 2021 Jun;81(8):881-893. doi: 10.1007/s40265-021-01525-x. Epub 2021 Apr 30.
8
Glucagon-like peptide-1 agonists.胰高血糖素样肽-1激动剂
BMJ. 2012 Jan 10;344:d7282. doi: 10.1136/bmj.d7282.
9
Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.从西格列汀切换至利拉鲁肽治疗英国 2 型糖尿病患者：一项长期成本效益分析。
Diabetes Obes Metab. 2018 Aug;20(8):1921-1927. doi: 10.1111/dom.13318. Epub 2018 May 3.
10
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.胰高血糖素样肽-1 受体激动剂对体重减轻的影响：随机对照试验的系统评价和荟萃分析。
BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771.

引用本文的文献

1
Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions.胰高血糖素样肽-1受体激动剂：演变、胃肠道不良反应及未来方向。
World J Gastrointest Pharmacol Ther. 2025 Sep 5;16(3):107148. doi: 10.4292/wjgpt.v16.i3.107148.
2
Exploratory Assessment of Preoperative GLP-1 Receptor Agonists Before Sleeve Gastrectomy: A Retrospective Matched Analysis.袖状胃切除术前GLP-1受体激动剂的探索性评估：一项回顾性匹配分析
Obes Surg. 2025 Sep 10. doi: 10.1007/s11695-025-08258-w.
3
Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.胰高血糖素样肽-1受体激动剂的获益-风险评估：对皮肤科医生和整形外科医生的启示
Dermatol Ther (Heidelb). 2025 Sep 9. doi: 10.1007/s13555-025-01537-5.
4
All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium-Glucose Cotransporter-2 Inhibitors.使用胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白-2抑制剂治疗的2型糖尿病成年患者的全因死亡率和胃肠道不良反应
Gastro Hep Adv. 2025 Jul 5;4(10):100736. doi: 10.1016/j.gastha.2025.100736. eCollection 2025.
5
GLP-1 Receptor Agonist Use in Patients Undergoing Distal Radius Fracture Surgery: A Retrospective Review of Perioperative Considerations.胰高血糖素样肽-1受体激动剂在桡骨远端骨折手术患者中的应用：围手术期考量的回顾性分析
Cureus. 2025 Jul 31;17(7):e89183. doi: 10.7759/cureus.89183. eCollection 2025 Jul.
6
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.司美格鲁肽和替尔泊肽用于射血分数保留的心力衰竭患者
JAMA. 2025 Aug 31. doi: 10.1001/jama.2025.14092.
7
Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots.阻力运动治疗射血分数保留的心力衰竭（HFpEF）与肥胖：针对骨骼肌异常和异位脂肪堆积
Physiologia. 2025 Mar;5(1). doi: 10.3390/physiologia5010010. Epub 2025 Feb 27.
8
Semaglutide Overdose in a Diabetic Patient: Suicidal Behavior and Multiorgan Failure.一名糖尿病患者的司美格鲁肽过量：自杀行为与多器官功能衰竭
Am J Case Rep. 2025 Aug 24;26:e947682. doi: 10.12659/AJCR.947682.
9
Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery.用于治疗糖尿病和肥胖症的胰高血糖素样肽-1受体激动剂：口服给药的优势
Front Drug Deliv. 2024 Nov 6;4:1456654. doi: 10.3389/fddev.2024.1456654. eCollection 2024.
10
Phenome-Wide Risk Evaluation of GLP-1 Receptor Agonist Use in Type 2 Diabetes with Real-World Data Across Multiple Healthcare Systems.利用多个医疗系统的真实世界数据对2型糖尿病患者使用胰高血糖素样肽-1受体激动剂进行全表型风险评估
medRxiv. 2025 Aug 15:2025.08.13.25333579. doi: 10.1101/2025.08.13.25333579.